共 36 条
- [11] Wells P.S., Anderson D.R., Rodger M., Forgie M., Kearon C., Dreyer J., Et al., Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis, N Engl J Med, 349, pp. 1227-1235, (2003)
- [12] Wells P.S., Owen C., Doucette S., Fergusson D., Tran H., Does this patient have deep vein thrombosis?, JAMA, 295, pp. 199-207, (2006)
- [13] Pisters R., Lane D.A., Nieuwlaat R., Vos C.B., Crijns H.J., Lip G.Y.H., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, pp. 1093-1100, (2010)
- [14] Ruiz-Gimenez N., Suarez C., Gonzalez R., Nieto J.A., Todoli J.A., Samperiz L., Et al., Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry, Thromb Haemost, 100, pp. 26-31, (2008)
- [15] Weitz J.I., Anticoagulation therapy in 2015: where we are and where we are going, J Thromb Thrombolysis, 39, pp. 264-272, (2015)
- [16] Pharma B.A.G., Xarelto® (rivaroxaban) Summary of Product Characteristics, (2016)
- [17] Bristol-Myers Squibb, Pfizer. Eliquis® (apixaban) Summary of Product Characteristics, (2016)
- [18] Pradaxa® (dabigatran etexilate) Summary of Product Characteristics, (2016)
- [19] Lixiana® (edoxaban) Summary of Product Characteristics, (2016)
- [20] Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., Et al., Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, pp. 799-808, (2013)